Intrinsiqq
OncoZenge AB logo

OncoZenge AB Financials

ONCOZ.XSTO

Compare

All currency values in kr millions unless otherwise noted

Scroll

Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenuekr 6kr 3kr 0kr 0kr 0kr 0
Cost of Revenue––––kr 0kr 0
Gross Profit––––kr 0kr 0
Total Operating Expenses––––kr 20kr 5
Operating Income-kr 25-kr 16-kr 9-kr 16-kr 20-kr 5
Non-Operating
Net Interest Expense-kr 1-kr 0-kr 0–kr 0kr 0
Income Tax Expensekr 0kr 0kr 0kr 0kr 3-kr 1
Net Income
Net Income-kr 26-kr 16-kr 9-kr 16-kr 47-kr 4
Per Share Data
Revenue Per Sharekr 0.41kr 0.22kr 0.00kr 0.00kr 0.00kr 0.00
EPS (Basic)-kr 2.03-kr 1.31-kr 0.74-kr 1.36-kr 3.98-kr 0.33
EPS (Diluted)-kr 2.03-kr 1.31-kr 0.74-kr 1.36-kr 3.98-kr 0.33
Shares Outstanding14.0M12.1M11.7M11.7M11.7M11.7M

OncoZenge AB (ONCOZ.XSTO) financials: revenue, profit and margins

OncoZenge AB (ONCOZ.XSTO) generated about SEK 6 million in revenue and -SEK 26 million in net income (a -452.0% net margin) over the trailing twelve months. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is OncoZenge AB's (ONCOZ.XSTO) revenue?+

OncoZenge AB generated about SEK 6 million in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is OncoZenge AB profitable?+

OncoZenge AB reported about -SEK 26 million in net loss over the trailing twelve months, a net margin of roughly -452.0%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are OncoZenge AB's profit margins?+

OncoZenge AB runs an operating margin of about -439.8%, a net margin of about -452.0%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How the market compares: How many US companies are profitable

Peers

Biotechnology · Pick stocks to compare with ONCOZ.XSTO

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
NXTCL.XSTONextCell Pharma AB
€0.01+18.52%50
KDEV.XSTOKDventures AB
kr 0.14+6.06%25
BIOSGN.XSTOBiosergen AB
No recent price20
HEART.XSTOScandinavian Real Heart AB
€1.28-0.39%10
2CUREX.XSTO2cureX AB
No recent price10
APOTEA.XSTOApotea AB
€9.00-0.94%71
XVIVO.XSTOXVIVO Perfusion AB
kr 197.15+1.00%44

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ONCOZ.XSTO

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.